Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100150 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
A Phase 2 study, sponsored by Neuren Pharmaceuticals Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02100150 is a Phase 2 study that was terminated before completion, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 32 participants.
The verdict
NCT02100150, a Phase 2 study, was terminated before completion, sponsored by Neuren Pharmaceuticals Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.
Interventions
- DRUG Placebo
- DRUG NNZ-2566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100150
The ClinicalTrials.gov registry entry for NCT02100150 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuren Pharmaceuticals Limited, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02100150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100150 about?
NCT02100150 is a clinical study titled "A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)". The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.
What is the current status of trial NCT02100150?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02100150?
The interventions under investigation include: Placebo (DRUG), NNZ-2566 (DRUG).
Who is sponsoring clinical trial NCT02100150?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.